AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present an overview of the company at the following investor conferences during the month of September:

  • Morgan Stanley Global Healthcare Unplugged Conference on September 13 at 1:35 p.m. ET
  • Robert W. Baird 2010 Healthcare Conference on September 14, at 9:30 a.m. ET
  • UBS 2010 Global Life Sciences Conference on September 22, at 2:00 p.m. ET

The conferences are being held in New York City.

A live webcast of each presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral contrast agent used in magnetic resonance imaging. For additional company information, please visit www.amagpharma.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.



CONTACT:

AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Finance

MEDIA:

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.